PRDM16

Across TCGA pan-cancer cohorts, PRDM16 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRDM16 data layer compared with 20 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PRDM16 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PRDM16 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

GBM, LUAD, and CCRCC are the cancer types where PRDM16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.375	0.652	.007	18	view →
LUAD	OS	Tertile	All	0.898	0.679	.012	9	view →
CCRCC	DFS	Median	All	0.608	1.000	.021	7	view →
LSCC	OS	Median	All	0.693	0.887	.020	2	view →
PDAC	DFS	Median	III,IV	0.554	0.243	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRDM16–GBM (OS)

Open the GBM breakdown →